Loading...
Market
What will be the peak stock price of Viridian Therapeutics in Q4 2024?
3
Viridian Therapeutics•Veligrotug•Clinical Activity Score•Viridian•Biologics License Application•Amgen
Resolution / Starting Odds
Below $20 • 25%
$20 - $30 • 25%
$30 - $40 • 25%
Above $40 • 25%
Stock market data from financial platforms like Yahoo Finance or Bloomberg
Story
Viridian Therapeutics Announces Positive Results from Phase 3 THRIVE Trial for TED with VRDN-001 Veligrotug
Sep 10, 2024, 11:06 AM
Viridian Therapeutics announced positive topline results from its Phase 3 THRIVE clinical trial of Veligrotug (VRDN-001), an experimental treatment for thyroid eye disease (TED). The results showed significant improvement in reducing eye bulging and achieving primary goals. Key findings include a 70% proptosis responder rate, 54% complete resolution of diplopia, and 64% reduction of Clinical Activity Score to 0 or 1. The treatment was well-tolerated with no treatment-related serious adverse events. Viridian plans to submit a Biologics License Application (BLA) in 2025. The results compared favorably to a similar drug already approved and sold by Amgen. A webcast to discuss the results is scheduled for September 10, 2024, at 8:00am ET.
View original story
Similar markets
Below $100 • 25%
$100 to $120 • 25%
$120 to $140 • 25%
Above $140 • 25%
Below $2 • 25%
$2 to $5 • 25%
Above $10 • 25%
Below $5 • 25%
$5 to $10 • 25%
$10 to $15 • 25%
Above $15 • 25%
Below $20 per share • 25%
$20-$24.99 per share • 25%
$25-$29.99 per share • 25%
$30 or above per share • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Less than 50% • 25%
50% to 100% • 25%
100% to 200% • 25%
More than 200% • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Above $40 • 25%
$30-$40 • 25%
$20-$30 • 25%
Below $20 • 25%
Below $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
Above $40 • 25%
Below $2 • 25%
$2 to $3 • 25%
$3 to $5 • 25%
Above $5 • 25%
